Besifloxacin

Besifloxacin is a fourth-generation fluoroquinolone antibiotic. The marketed compound is besifloxacin hydrochloride. It was developed by SSP Co. Ltd., Japan, and designated SS734. SSP licensed U.S. and European rights to SS734 for ophthalmic use to InSite Vision Incorporated (OTCBB: INSV) in 2000. InSite Vision developed an eye drop formulation (ISV-403) and conducted preliminary clinical trials before selling the product and all rights to Bausch & Lomb in 2003.

Properties:

Density: 1.47 g/cm3

Boiling Point: 606.976ºC at 760 mmHg

Flash Point: 320.887ºC

Refractive Index: 1.649

Vapor Pressure:0mmHg at 25°C

Bacterial inhibitor Related Products:

Pretomanid; Pyrazinamide; Sulfanilamide; Walrycin B; Daptomycin; Tigecycline; Rifabutin; Biapenem; Teicoplanin; Cefditoren Pivoxil; Cefdinir; Azithromycin; Trimethoprim; Vancomycin HCl; Amoxicillin; Dalbavancin; Cefoxitin acid; Ceftibuten dihydrate; Solithromycin; Cefditoren; Dalbavancin HCl; Cefoxitin Sodium; Besifloxacin Hydrochloride; Pleuromutilin

1: Proksch JW, Ward KW. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits. J Ocul Pharmacol Ther. 2010 Oct;26(5):449-58. PubMed PMID: 20874668.

2: Sanders ME, Moore QC 3rd, Norcross EW, Sanfilippo CM, Hesje CK, Shafiee A, Marquart ME. Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis. Cornea. 2011 Jan;30(1):83-90. PubMed PMID: 20847656.

3: Yoshida J, Kim A, Pratzer KA, Stark WJ. Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients. J Cataract Refract Surg. 2010 Sep;36(9):1499-502. PubMed PMID: 20692561.